3:55
Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
Xiaoni Gao, Chengcheng Hong, Yang Xie, Xiangtai Zeng
A rare thyroid cancer causes more than half of all deaths from thyroid cancer, yet makes up only a small fraction of cases. This review asks whether the answer is to target the cancer’s weak spots, awaken the immune system, or combine both. Anaplastic thyroid carcinoma makes up only about two percent of thyroid cancers, yet causes more than half of thyroid-cancer deaths. This review asks whether targeted drugs, immunotherapy, or their combination can change that outlook.
